Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8750317 | 0.83 | MEN1 (0.37) | MEN1LMNAKMT2A | |
| SCHEMBL1163926 | 0.72 | — | — | |
| SCHEMBL225281 | 0.72 | — | — | |
| Alcohol SCHEMBL28340147 | 0.71 | CYP2A6 (0.36) | CYP2A6PKMNPC1RAB9AL3MBTL1 | |
| SCHEMBL447131 | 0.70 | — | — | |
| SCHEMBL9696347 | 0.69 | PRKDC (0.41) | CYP2A6PKMNPC1RAB9AL3MBTL1 | |
| SCHEMBL868397 | 0.67 | MAPT (0.35) | MAPT | |
| SCHEMBL577560 | 0.67 | — | — | |
| SCHEMBL5100777 | 0.67 | NPC1 (0.32) | PKMNPC1RAB9AL3MBTL1ATM | |
| SCHEMBL482135 | 0.67 | CYP2A6 (0.39) | KDM4ECYP2A6ERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-6319922-B1 | ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-11-20 | — | — | US | disclosed |
| EP-1133488-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0765331-B1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | AVECIA LTD (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000031067-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| US-5880188-A | PROTECTING MEDIUM SUSCEPTIBLE TO MICROBIAL ATTACK BY TREATING WITH SPECIFIED OXABOROLE COMPOUND | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | KDM4E 3044/4885CYP2A6 117/4885PKM 2899/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | KDM4E 1160/4885CYP2A6 391/4885PKM 3579/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | KDM4E 1589/4885CYP2A6 1752/4885PKM 2245/4885 |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | KDM4E 4514/4885CYP2A6 3489/4885PKM 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.